Key takeaways:
Once-daily oral Lipfendra lowers LDL-C by roughly 56% to 58%, which is comparable to PCSK9 injectables.
There is no data on cardiovascular outcomes yet. It will be a few more years until it’s known how Lipfendra affects actual clinical outcomes.
There are no drug interactions and no contraindications. Patients have to take it on an empty stomach and wait 30 minutes before eating, though. Taking it with or after a meal cuts absorption in half.
If you treat hypercholesterolemia, here’s a situation you might be familiar with: Your patient is on high-intensity atorvastatin plus ezetimibe. Their LDL-C is still high, but they’ve already refused a PCSK9 injection.
You now have another option in this situation. In July 2026, the FDA approved Lipfendra (enlicitide). It’s the first PCSK9 inhibitor you can prescribe as a pill.
Lipfendra works well. But which patients are the right candidates for it and what do you need to look out for? Here’s how to navigate the newest FDA-approved cholesterol medication.
What is Lipfendra?
Lipfendra blocks PCSK9, the same target as evolocumab (Repatha) and alirocumab (Praluent). Blocking it leaves more LDL receptors on the liver available to pull LDL-C out of the blood.
The difference between these PCSK9 inhibitors is the route of administration. Repatha and Praluent are monoclonal antibodies that must be injected. But Lipfendra is a much smaller molecule that can survive the gut, so it can be taken orally.
Lipfendra is approved to treat hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), in adults as an add-on to diet and exercise. Once started, you can expect to see LDL-C levels drop by 4 weeks.
Efficacy data
Two placebo-controlled clinical trials supported the approval. Neither was designed to measure anything beyond changes to the lipid panel. Both included patients with hyperlipidemia despite treatment with a statin:
If history of a major ASCVD event, LDL-C level of 55 mg/dL or greater (≥1.42 mmol/L)
If no history of a major ASCVD event, LDL-C level of 70 mg/dL or greater (≥1.81 mmol/L)
Here’s what the data showed:
Trial | Patient population | LDL-C drop vs. placebo |
|---|---|---|
Phase 3 | ~2,900 adults with CAD or at high risk | 56% |
Phase 3 | ~300 adults with HeFH | 58% |
Secondary outcomes
Both trials ran for a full year. The primary endpoint was LDL-c at 24 weeks, but the secondary endpoints can still tell us a little more.
First, the LDL-C reduction held over time. At 52 weeks it was still 48% below placebo in the larger trial and 62% below placebo in the HeFH trial. The larger trial's number wasn’t as good as it was at 24 weeks, but that's mostly because of patients who stopped taking the drug, not because the drug worked less well.
Also, the other lipid numbers, measured at 24 weeks, moved the same direction. Lipoprotein(a), in particular, fell by almost 30%. That’s important because statins and ezetimibe don't budge Lipoprotein(a).
Still, none of these are clinical outcomes. Nobody has shown that lowering someone's Lipoprotein(a) levels actually prevents a heart attack.
What we don't know yet
The primary outcome in both trials was LDL-C at 24 weeks. There were no apparent differences in serious adverse events or deaths, but neither trial was designed to evaluate cardiac outcomes. The trial that will assess these clinical outcomes, CORALreef Outcomes, is expected to be completed in December 2029.
And there’s another open question raised in NEJM after the main trial was published. Because the studies only ran for 52 weeks, nobody knows whether the LDL-C lowering effects hold over time. One concern is compensatory PCSK9 up-regulation, the idea that the body might compensate for the PCSK9 inhibition by simply making more PCSK9 over time.
So far, Repatha and Praluent have proven they prevent major cardiovascular events (and are approved for this indication), while Lipfendra has only demonstrated that it lowers the number that causes them. It’s a reasonable bet that Lipfendra will end up proving that it can prevent heart attacks and strokes just like the injectables, but it’s not a proven one.
Prescribing tips
Prescribing Lipfendra is actually quite simple. There's one dose, no titration, and no adjustment for kidney or liver disease.
The one thing worth spending counseling time on is timing. The fasting window is important. Patients who eat food within 30 minutes of taking the drug only absorb half of it. The wait is about food and drink, though, not pills. Patients can take their other morning medications right along with it.
Here’s a quick guide to everything you need to know:
Dose | One 20 mg tablet, once daily |
When | Morning, on an empty stomach |
With | Water, black coffee, or plain tea only. |
Then | Wait at least 30 minutes before food or any other drink |
Missed dose | Take it at any point throughout the day, but you still need to wait 30 minutes before eating. |
Contraindications | None |
Kidney or liver disease | No dose change, including dialysis |
Pregnancy | Do not use |
Drug interactions | None identified |
Monitoring | Check LDL-C when it’s convenient to do so — the effect shows by 4 weeks |
Side effects | Mild. In the larger trial, adverse effects and discontinuations matched placebo. In the smaller HeFH trial, there was slightly more diarrhea and dizziness than in placebo. |
Comparison to injectables
The choice usually comes down to two questions: Will your patient accept an injection, and how much does the missing outcomes data matter at their risk level?
Here’s a breakdown on comparing Lipfendra to current injectables:
Lipfendra | Repatha / Praluent | |
|---|---|---|
Route | Daily pill | Injection every 2-4 weeks |
LDL-C drop | ~56%-58% | |
Outcomes data | Not until 2029 | Yes, the injectables have been proven to decrease cardiac events. |
Daily hassle | 30-minute fasting window | None |
List price | ~$380 | ~$690 |
The bottom line
The newly approved oral PCSK9 inhibitor Lipfendra lowers LDL-C as much as a PCSK9 inhibitor injection — 56% in a broad high-risk group, 58% in HeFH. It’s the first once-daily pill in its class and comes with a clean safety and interaction profile thus far.
What it lacks is proof that this translates into fewer heart attacks and strokes. It’s a good guess that it will, but that answer is still a few years away.
For the patient who won't inject or prefers not to, Lipfendra is a good option without too many downsides. For the patient already injecting without trouble, on the other hand, there's no reason to switch yet.
Why trust our experts?
References
Ballantyne, C. M., et al. (2025). Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous familial hypercholesterolemia: A randomized clinical trial. JAMA.
Farnier, M., et al. (2016). Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials. International Journal of Cardiology.
Navar, A. M., et al. (2026). A placebo-controlled trial of the oral PCSK9 inhibitor enlicitide. The New England Journal of Medicine.
Sabatine, M. S., et al. (2017). Evolocumab and clinical outcomes in patients with cardiovascular disease. The New England Journal of Medicine.
Steinzor, P. (2026). Oral PCSK9 inhibitor enlicitide lowers LDL by 57% at 24 weeks. AJMC.
U.S. Food and Drug Administration. (2026). FDA approves first oral PCSK9 inhibitor to lower LDL cholesterol in adults with high cholesterol.
